Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal

Colorectal Disease

Volumn 13, Issue 5, 2011, Pages 555-560

  Regadas, F S P ^a   Pinto, R A ^a   Murad Regadas, S M ^a   Canedo, J A ^a   Leal, M ^a   Nogueras, J J ^a   Wexner, S D ^a  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

Ileostomy reversal; Immunosuppressive agents; Inflammatory bowel disease; Infliximab

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE;

ABDOMINAL ABSCESS; ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; COLITIS; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ENTEROCUTANEOUS FISTULA; FEMALE; HERNIA; HUMAN; ILEOSTOMY; ILEUS; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE SURGERY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSTRUCTION; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; SEPSIS; SMALL INTESTINE OBSTRUCTION; SMALL INTESTINE RESECTION; STEROID THERAPY; TREATMENT OUTCOME; ULCERATIVE COLITIS; WOUND INFECTION;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ILEOSTOMY; IMMUNOSUPPRESSIVE AGENTS; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79953321418     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2010.02186.x     Document Type: Article

References (31)

1. Hasegawa H, Radley S, Morton DG, Keighley MR. Stapled versus sutured closure of loop ileostomy: a randomized controlled trial. Ann Surg 2000; 231: 202-4.
2. Garcia-Botello SA, Garcia-Armengol J, Garcia-Granero E et al. A prospective audit of the complications of loop ileostomy construction and takedown. Dig Surg 2004; 21: 440-6.
3. Bakx R, Busch OR, Bemelman WA, Veldink GL, Slors JF, Van Lanschot JJ. Morbidity of temporary loop ileostomies. Dig Surg 2004; 21: 277-81.
4. Colombel JF, Loftus EV Jr, Tremaine WJ et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99: 878-83.
5. Marchal L, D'Haens G, Van Assche G et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19: 749-54.
6. Schluender SJ, Ippoliti A, Dubinsky M et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007; 50: 1747-53.
7. Selvasekar CR, Cima RR, Larson DW et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204: 956-62.
8. Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51: 1202-10.
9. Yamamoto T, Keighley MR. Factors affecting the incidence of postoperative septic complications and recurrence after strictureplasty for jejunoileal Crohn's disease. Am J Surg 1999; 178: 240-5.
10. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004; 53: 780-2.
11. Punchard NA, Boswell DJ, Greenfield SM, Thompson RP. Mechanism of action of 5-aminosalicylic acid. Mediat Inflamm 1992; 1: 151-65.
12. Hyde GM, Jewell DP, Kettlewell MGW, Mortensen NJMcC. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 44: 1436-40.
13. Heimann TM, Greenstein AJ, Mechanic L, Aufses AH Jr. Early complications following surgical treatment for Crohn's disease. Ann Surg 1985; 201: 494-8.
14. Post S, Betzler M, von Ditfurth B, Schürmann G, Küppers P, Herfarth C. Risks of intestinal anastomoses in Crohn's disease. Ann Surg 1991; 213: 37-42.
15. Lindhagen T, Ekelund G, Leandoer L, Hildell J, Lindström C, Wenckert A. Crohn's disease in a defined population course and results of surgical treatment. I. Small bowel disease. Acta Chir Scand 1983; 149: 407-13.
16. Lindhagen T, Ekelund G, Leandoer L, Hildell J, Lindström C, Wenckert A. Crohn's disease in a defined population course and results of surgical treatment. Part II. Large bowel disease. Acta Chir Scand 1983; 149: 415-21.
17. Allsop JR, Lee EC. Factors which influenced postoperative complications in patients with ulcerative colitis or Crohn's disease of the colon on corticosteroids. Gut 1978; 19: 729-34.
18. Knudsen L, Christiansen L, Jarnum S. Early complications in patients previously treated with corticosteroids. Scand J Gastroenterol 1976; 37: 123-8.
19. Baert FJ, D'Haens GR, Peeters M et al. Tumor necrosis factor-alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-8.
20. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 345: 1098-104.
21. Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population-based cohort from Stockholm County. Gut 2004; 53: 849-53.
22. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
23. Schneeweiss S, Setoguchi S, Weinblatt ME et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.
24. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
25. Appau KA, Fazio VW, Shen B et al. Use of Infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008; 12: 1738-44.
26. Kaidar-Person O, Person B, Wexner SD. Complications of construction and closure of temporary loop ileostomy. J Am Coll Surg 2005; 201: 759-73.
27. Leung TT, MacLean AR, Buie WD, Dixon E. Comparison of stapled versus handsewn loop ileostomy closure: a meta-analysis. J Gastrointest Surg 2008; 5: 939-44.
28. Wong KT, Remzi FH, Gorgun E et al. Loop ileostomy closure after restorative proctocolectomy: outcome in 1504 patients. Dis Colon Rectum 2005; 48: 243-50.
29. Sagar PM, Lewis W, Holdsworth PJ, Johnston D. One-stage estorative proctocolectomy without temporary defunctioning ileostomy. Dis Colon Rectum 1992; 35: 582-88.
30. Wexner S, Taranow DA, Johansen OB, Itzkowitz F, Daniel N, Nogueras JJ et al. Loop ileostomy is a safe option for fecal diversion. Dis Colon Rectum 1993; 36: 349-354.
31. Lim M, Sagar P, Abdulgader A, Thekkinkattil D, Burke D. The impact of preoperative immunomodulation on pouch-related septic complications after ileal pouch-anal anastomosis. Dis Colon Rectum 2007; 50: 943-51.